CSRxP Urges House Lawmakers to Pass First Drug Pricing Bills of the Year

May 8, 2019

Vote On Orange And Purple Book Bills Should Mark Beginning Of A Series Of Legislative Actions To Deliver On Rising Drug Prices

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) today released a statement encouraging members of the U.S. House of Representatives to pass the first two bills on drug pricing scheduled to be brought to the House floor in the 116th Congress.  Those bills are the Purple Book Continuity Act of 2019 and Orange Book Transparency Act of 2019.

“The momentum in Washington to take action on the crisis of rising prescription drug prices and deliver relief for American patients with market-based solutions has never been greater,” said CSRxP executive director Lauren Aronson.  “We urge lawmakers in Congress to pass the Purple and Orange book improvements, in overwhelmingly bipartisan fashion, and to keep the momentum going by swiftly bringing additional market-based solutions to the floor for a vote by the full House.”

In addition to the Purple Book Continuity Act of 2019 and Orange Book Transparency Act of 2019, several other market-based solutions targeting drug prices have advanced through the committee process in the House and could be brought to the floor for a vote by the whole body, including the CREATES Act, the Protecting Consumer Access to Generic Drugs Act of 2019 and the Prescription Drug STAR Act.

“The Orange and Purple Book bills being considered this week represent a first step in the right direction,” Aronson added.  “Lawmakers should see their bipartisan passage as just the beginning of a series of legislative activity to advance critical market-based solutions to lower prescription drug prices and provide relief for American patients.”